Fundraise / allotmentFiled on BSE ·
Krsnaa Diagnostics receives in-principle approval for 16.21 lakh convertible warrants issue
Krsnaa Diagnost. · Healthcare Services
What the filing says
- Approval received from BSE and NSE for issuing 16,21,000 convertible warrants on preferential basis
- Warrants convertible into equal number of equity shares at face value ₹5 each, issue price ₹566 per warrant
- Warrants to be allotted to Promoter and Promoter Group under Regulation 28(1) of SEBI LODR, dated October 8, 2026
Original filing
Announcement Under Regulation 30 (LODR)-In-Principle Approval For Issue Of Warrants
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Waaree Energies
Electrical Equipment
Revenue growth 40%+Margin up 2%+
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Krsnaa Diagnost.
Other fundraise / allotment filings this fortnight
- Fundraise / allotmentMIC Electronics LtdEbisu Global Opportunities Fund Limited acquires shares in MIC Electronics Limited
- Fundraise / allotmentBhagyanagar India LtdBhagyanagar India Limited allotment of shares by Tieramet Limited after demerger
- Fundraise / allotmentSuryoday Small Finance Bank LtdSuryoday Small Finance Bank allots ₹200 crore subordinate NCDs on private placement
- Fundraise / allotmentSMC Global Securities LtdSMC Global Securities to discuss Preferential Warrant Issuance on Oct 14, 2026
- Fundraise / allotmentEmbassy Developments LtdEmbassy Developments Limited credit rating upgraded to IVR A/Stable on Oct 9, 2026
- Fundraise / allotmentCanara HSBC Life Insurance Company LtdCanara HSBC Life Insurance Ltd reports Q2 FY2026-27 financials and board actions
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.